RAGE Biotech is developing novel therapeutics targeting the Receptor for Advanced Glycation End-products (RAGE) for patients with difficult-to-treat inflammatory disease.
IN INFLAMMATION, RAGE MATTERS
RAGE is an important therapeutic target in a wide range of inflammatory diseases.
RAGE is a 'sensing receptor' that recognises a large number of potential triggers.
This makes it difficult to develop a drug to RAGE using traditional approaches.
At RAGE Biotech, we are harnessing cutting edge RNA-targeting and therapeutic peptide technologies to bring an effective RAGE inhibitor to the clinic.
Our aim is to improve the lives of people with chronic inflammatory conditions around the world.
MEDIA & PRESS UPDATES
AUSTRALIAN UNIVERSITIES JOIN FORCES TO TACKLE INFLAMMATORY LUNG DISEASE
8 July, 2020
A new spin-out company, RAGE Biotech, will develop novel therapies designed to help patients with chronic inflammatory lung diseases such as severe asthma, cystic fibrosis and chronic obstructive pulmonary disease (COPD), supported by investment from IP Group, Monash University (Monash) and The University of Western Australia (UWA).
Globally, COPD is the fourth leading cause of mortality and morbidity, with chronic inflammation being a key feature and driver of disease progression in COPD, cystic fibrosis and severe asthma.
RAGE Biotech is developing new approaches to modulate the receptor for advanced glycation end-products (RAGE), an important target in chronic inflammation with links to COPD and cystic fibrosis.
RAGE Biotech Pty Ltd
ACN 640 194 770
40 City Road, Southbank, Victoria 3006, Australia